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Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with
anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplas-
mic membrane in humans, but their expression has been demonstrated in several human
malignant tumors. Racotumomab is an anti-idiotype mAb speciﬁc to P3 mAb, an antibody
which reacts to NeuGc-containing gangliosides, sulfatides, and other antigens expressed in
tumors. Preparations containing racotumomab were able to induce a strong anti-metastatic
effect in tumor-bearing mice. Different Phase I clinical trials have been conducted in patients
with advanced melanoma, breast cancer, and lung cancer.The results of these clinical trials
demonstrated the low toxicity and the high immunogenicity of this vaccine. The induced
antibodies recognized and directly killed tumor cells expressing NeuGcGM3. A Phase II/III
multicenter, controlled, randomized, double blind clinical trial was conducted to evalu-
ate the effect of aluminum hydroxide-precipitated racotumomab vaccine in overall survival
in patients with advanced non-small cell lung cancer. The clinical results of this study
showed a signiﬁcant clinical beneﬁt in the patients who were treated with the anti-idiotype
vaccine.
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Actively induced immunotherapy is one of the most promising
ﬁelds in cancer research and numerous approaches are being stud-
ied to design effective cancer vaccines. An approach to generate
an effective immune response against tumor-associated antigens
involves the use of an anti-idiotype monoclonal antibody (Ab2
mAb). The use of Ab2 as a vaccine is a consequence of Jerne’s
idiotypic network theory, which postulates that, due to the large
potential diversity of immunoglobulin variable regions, the idio-
type repertoire can mimic the universe of self and foreign epitopes
(Jerne, 1974). Thus, properly selected anti-idiotypic antibodies
could act as tumor-associated antigen surrogates.
Studies in animal models have demonstrated the efﬁcacy of
these vaccines for triggering the immune system to induce spe-
ciﬁc and protective immunity against tumors of different origin
(Bhattacharya-Chatterjee et al., 2001; Mohanty et al., 2007). In
the clinical setting anti-idiotypic antibodies are also being actively
evaluated for the treatment of malignant diseases (de Cerio et al.,
2007). In fact, several studies have validated the capacity of anti-
idiotype mAbs to mimic different kind of antigens in cancer
patients, inducing humoral and cellular responses against the
nominal antigens. One of these antibodies designated 3H1 mim-
ics a speciﬁc epitope on the carcinoembryonic antigen (CEA), a
tumor-associated antigen expressed on most gastrointestinal ade-
nocarcinomas. This anti-idiotype mAb was used in Phase I clinical
trials in advanced colorectal cancer patients and demonstrated
speciﬁc active immunity to CEA, inducing anti-CEA antibodies
and T cell proliferative responses. The level of the immune
response correlated directly with the time to progression and sur-
vival. More recently these researchers performedaPhase III clinical
trial with 630 patients with advanced colorectal cancer combining
5-ﬂuorouracil and leucovorin with either 3H1 anti-idiotype mAb
or placebo. Although the addition of 3H1 did not improve the
overall patient outcome, again there was an improvement in the
survival of the patients that developed strong anti-CEA responses
(Foon et al., 1995, 1997, 1999; Bhattacharya-Chatterjee et al., 2000;
Chong et al., 2006).
Mittelman et al. (1990, 1992) demonstrated the capacity of
the anti-idiotype mAb MK2-23 to mimic a high molecular
weight human melanoma antigen (HMW-MAA) and to induce
an anti-tumor response in melanoma patients, which included
the reduction in the size of metastatic lesions in some of the
patients. In these studies the survival of the patientswhodeveloped
anti-HMW-MAA antibodies was also signiﬁcantly longer.
An anti-idiotype antibody that has shown to activate T cell
responses against the nominal antigen is the 105AD7. This anti-
body has both amino acid and structural homology with the
complement regulatory protein CD55, a glycoprotein that protects
the cells from the attack by complement and which is overex-
pressed in osteosarcoma and colorectal cancer cells. Some of the
osteosarcoma patients vaccinated with 105AD7 elicited an IFN-
gamma T cell response against the vaccine, and TNF-alpha and
GM-CSF responses not only to the vaccine, but also toward the
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native antigen. This antibody was also injected in colorectal can-
cer patients, where again it induced proliferative responses and
TNF-alpha and GM-CSF secretion against the nominal antigen.
These researchers have not seen correlation between the induced
T cell responses and patient’s survival, probably due to the small
number of patients included in the studies (Robins et al., 1991;
Ullenhag et al., 2006, 2008).
Abagovomab, an anti-idiotype mAb directed against CA125,
has shown to induce active immune response against this tumor-
associated antigen in a Phase Ib/II clinical trial in advanced ovarian
cancer patients. In this study, those patients who developed
anti-anti-idiotype (Ab3) response had a signiﬁcant longer overall
survival (Reinartz et al., 2004). On the basis of these encour-
aging results, a Phase II/III pivotal study (MIMOSA study) to
evaluate abagovomab as a maintenance therapy in ovarian can-
cer patients with no residual disease after frontline therapy was
conducted (Pﬁsterer et al., 2011a). In this study was enrolled
888 patients, and 593 women were treated with abagovomab
and 295 women were assigned to treatment in the placebo arm.
Unfortunately, the results of this study showed that abagovomab
maintenance treatment after debulking surgery and successful
platinum and taxane ﬁrst-line chemotherapy did not prolong
progression-free survival in advanced ovarian cancer patients
(Pﬁsterer et al., 2011b).
Also, anti-idiotype mAbs have been used to mimic non-
protein antigens in patients with different tumors. One example
of these kind of antigens are the gangliosides which are sialic acid-
containing glycosphingolipids normally expressed in the mem-
brane of eukaryotic cells (Wiegandt, 1985), but their expression
patterns change during oncogenic transformation (Hakomori,
1985; Irie and Ravindranath, 1990).
The anti-idiotype mAb 1A7, which functional mimics the gan-
glioside GD2, (Sen et al., 1998) has been used as an anti-idiotype
vaccine (TriGem) in patients with advanced melanoma (Foon
et al., 1998, 2000). The immunization with this anti-idiotype vac-
cine elicited a strong anti-GD2 antibody response that speciﬁcally
reacted with tumor cells expressing GD2. Although the studies
included a small number of patients, the results suggested that
TriGem vaccine may have a role in preventing disease progres-
sion and in increasing survival time for patients with advanced
malignant melanoma (Foon et al., 2000).
Another antibody used as an anti-idiotype vaccine in can-
cer patients is the mAb Bec2, which mimics GD3 ganglioside
(Chapman and Houghton, 1991). This antibody was studied in
melanoma and small cell lung cancer (SCLC) patients, where
it induced speciﬁc anti-GD3 antibodies, but only in a low per-
centage of patients (McCaffery et al., 1996; Grant et al., 1999).
Furthermore these antibodies were hardly detectable by TLC
immunostaining or ﬂow cytometry (Ritter et al., 1991). Despite
the low frequency of anti-GD3 antibodies induction in the ﬁrst
trials, a Phase III clinical trial with 515 SCLC patients with a major
response to chemotherapy and chest radiationwas performedwith
this antibody. Only one third of the patients elicited an anti-GD3
response. Although this trial failed to show any survival advantage
for vaccinated patients, a trend toward prolonged survival was
observed in those patients who developed the humoral response
(Giaccone et al., 2005).
NeuGc-CONTAINING GANGLIOSIDES ARE ATTRACTIVE
TARGETS FOR IMMUNOTHERAPY OF TUMORS
In particular the Neu-glycolyl (NeuGc)-neuraminic acid variant
of gangliosides is widely expressed inmostmammalian tissues, but
is rarely found in normal human cells. The lack of expression of
this type of sialic acid in humans is due to the inactivating muta-
tion in the CMP-Neu5Ac hydroxylase gene, enzyme responsible
for Neu5Gc biosynthesis of Neu5Gc-containing molecules (Chou
et al., 1998; Irie and Suzuki, 1998; Olson and Varki, 2003). How-
ever, the presence of NeuGc-neuraminic acid residues has been
reported in different human tumors, detected by antibodies and
by chemical analysis (Higashi et al., 1984, 1988; Hirabagashi et al.,
1987; Miyake et al., 1990; Devine et al., 1991; Marquina et al., 1996;
Malykh et al., 2001; van Cruijsen et al., 2009; Scursoni et al., 2010),
where they are known to be immunogenic (Nguyen et al., 2005).
Additionally, recent experimental data suggest that NeuGcGM3
ganglioside is relevant for tumor progression (de León et al., 2006).
The most accepted theory for this phenomenon is the incorpo-
ration of Neu5Gc from dietary sources. Free sialic acids from the
medium can be taken up into cells via pinocytosis. The content
of the resulting pinocytotic vesicles and endosomes would even-
tually be delivered to the lysosome, where a sialic acid transporter
then delivers the molecules into the cytosol (Bardor et al., 2005).
The explanation for the differential expression of these antigens
in human normal and tumor tissues is that the rapidly grow-
ing tumor tissues might be more efﬁcient at scavenging Neu5Gc
from dietary sources. Furthermore, it has been proposed that
the preferential expression of NeuGc in cancers is closely associ-
ated with tumor hypoxia. Hypoxic culture of tumor cells induces
expression of a sialic acid transporter, sialin, and enhances the
incorporation of non-human sialic acid from the external milieu
(Yin et al., 2006).
RACOTUMOMAB ANTI-IDIOTYPE ANTIBODY
We ﬁrst generated a mAb, named P3, which distinguish between
NeuGc and NeuAc gangliosides (Vázquez et al., 1995; Moreno
et al., 1998). ThismAb also reactedwith humanmelanomas, breast
and lung tumors (Vázquez et al., 1995; Alfonso et al., 2002; Alfonso
et al., 2007; Neninger et al., 2007). Then, by immunizing Balb/c
mice with P3 mAb we obtained an anti-idiotype mAb, named
ﬁrst 1E10 and now racotumomab. This IgG1 Ab2 mAb, was able
to block the binding of the Ab1 mAb to NeuGcGM3 (Vázquez
et al., 1998).
Our hypothesis was that racotumomab could act as a surrogate
of NeuGc-gangliosides generating autologous antibodies in the
immunized species which react with the Ab2 idiotype and with
the NeuGc-containing gangliosides.
PRECLINICAL DATA
We tested the hypothesis using different animal models with a
different NeuGc-sialic acid expression: mice and monkeys that
express NeuGc-glycoconjugates (Chou et al., 1998; Hayakawa
et al., 2001) and chickens, which do not express NeuGc-glyco-
conjugates in their normal tissues (Fujii et al., 1982; Ledeen and
Yu, 1982).
Animals received different doses of preparations containing
racotumomab and when we evaluated the serological antibody
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response we found that all animals of the different species devel-
oped Ab3 response. It is noteworthy that in monkeys and chickens
where racotumomab is a xenogenic immunoglobulin the serolog-
ical response against racotumomab was stronger when compared
with other isotype-matched mAb used as a control (immunodom-
inance of the idiotype determinants). Besides, the Ab3 antibodies
generated by immunization with racotumomab mAb were char-
acterized to share idiotopes with P3 mAb (Ab1), as evidenced by
their capacity of inhibiting racotumomab binding to P3mAb (Ab3
Id+; Vázquez et al., 1998; Hernández et al., 2005).
In contrast, when the antibody response against NeuGc-
containing gangliosides induced by racotumomab immunization
was studied, a completely different pattern of response was
detected. In mice and monkeys, no speciﬁc humoral response
against NeuGc-containing gangliosides was detected in the sera
of racotumomab immunized animals. In the case of mice and
monkeys, since NeuGc-containing gangliosides are normal tissue
components (Ledeen and Yu, 1982), tolerance mechanisms could
be avoiding the immune response against these antigens. These
mechanisms are still unknown, but as it has been demonstrated
for other self-antigenmodels (Fillatreau et al., 2002; Takahashi and
Sakaguchi, 2003), one possibility is the existence of T and/or B reg-
ulatory cells that would modulate the antibody response against
NeuGc-containing gangliosides.
On the other hand, most chickens in our study developed
a speciﬁc Ab3 response against NeuGcGM3 and NeuGcGM2
gangliosides (Ab3 Ag+), due to the immunization with racotu-
momab (Hernández et al., 2005). In addition, Ag+Id-antibodies
were produced in chickens immunized with racotumomab. This
was demonstrated by the reactivity of hyperimmune sera to
NeuGcGM3 ganglioside after the adsorption of hyperimmune
chickens sera with racotumomab, which abrogate the antibody
response against this Ab2 (Hernández et al., 2005). The mech-
anism responsible for the generation of these antibodies is still
unknown. A natural immune network could be involved in the
generation of this unusual antibody “parallel set”.
Although these results, it is known that the induction of
antigen-speciﬁc humoral immune response is not predictive of the
biological effect induced by an anti-idiotype mAb. Thus, we stud-
ied the effect of different preparations containing racotumomab
in different experimental tumor murine models.
In BALB/c mice, vaccination with several intraperitoneal doses
at 14-day intervals of racotumomab coupled to keyhole limpet
hemocyanin in Freund’s adjuvant, signiﬁcantly reduced subcuta-
neous tumor growth of F3II carcinoma cells and the formation
of spontaneous lung metastases. The effect of racotumomab as a
biological response modiﬁer on lung colonization was evaluated
in C57BL/6 mice injected with B16 melanoma cells. Interestingly,
intravenous administration of uncoupled racotumomab antibody,
10–14 days after inoculation of tumor cells, dramatically reduced
the number of experimental metastases in comparison with lungs
from mice treated with an irrelevant IgG (Vázquez et al., 2000).
Later, we evaluated the anti-metastatic effect of racotumomab
in Alum adjuvant (racotumomab-Alum) in the 3LL-D122 Lewis
lung carcinoma model. Racotumomab-Alum immunization was
tested in two different settings distinguished by the frequency of
the immunizations, the amount of vaccine and the initiation of
the vaccine schedule related to the tumor challenge. Independently
to the immunization schedule, racotumomab-Alum promoted a
signiﬁcant reduction of spontaneous lung metastases. The ther-
apeutic effect was associated to the increment in the number of
T cells inﬁltrating metastases, a reduction of new blood vessels
formation, and the increment of apoptotic tumor cells in lung
nodules. It is noteworthy that active immunization with the mAb
in Alum does not induce measurable antibodies to racotumomab
molecule, the NeuGcGM3 or tumor cells, which may suggest a
different mechanism which has to be elucidated (Diaz et al., 2009).
More recently, preclinical studies were carried out with the
main objective to determine the anti-tumor effect of racotumo-
mab-Alum vaccine coadministered with low dose of cyclophos-
phamide in a murine mammary carcinoma model, based on
their potentially shared antiangiogenic properties and/or a com-
plementary proapoptotic effect by racotumomab-Alum vaccine.
The results of the study showed that the combination enhanced
the efﬁcacy of chemotherapy or immunotherapy alone in the F3II
carcinoma model, both when the mAb was obtained from mice
ascites ﬂuid or from bioreactor supernatant (Fuentes et al., 2010;
Machado et al., 2011).
CLINICAL DATA
Taking in account the preclinical results together with the results
of the toxicology studies, and after the approval of the Ethical
Committees of the hospitals and the Regulatory agencies, differ-
ent Phase I clinical trials were performed in advanced melanoma
(Alfonso et al., 2002), breast cancer (Díaz et al., 2003; Guth-
mann et al., 2006; Soriano et al., 2011), and SCLC and non-SCLC
(NSCLC;Alfonso et al., 2007; Neninger et al., 2007), with the main
goals of evaluate the safety and the immunogenicity of raco-
tumomab vaccine. All the patients had previously received the
oncospeciﬁc treatment established in the Oncological Therapeutic
Standards. In most of these clinical trials the patients were injected
intradermally with 10 doses of 1 or 2mgof racotumomab-Alumas
base treatment: the ﬁrst four or ﬁve doses at 2-week intervals and
the remaining six every 28 days. Reimmunizations were adminis-
tered if the patients had a favorable clinical status. The results of
these Phase I clinical trials evidenced that racotumomab vaccine
was well tolerated. Toxicity consisted mainly of local reaction at
the injection site with erythema and induration that disappeared
in a few days (adverse events grade I/II according to NCI-CTC
criteria).
Racotumomab-Alum vaccine resulted very immunogenic, a
strong, and speciﬁc response against NeuGc-containing ganglio-
sides was detected in the sera of most of the immunized patients by
ELISA and TLC-immunostaining (Alfonso et al., 2002; Díaz et al.,
2003; Guthmann et al., 2006; Neninger et al., 2007). One interest-
ing ﬁnding was the detection of a high level of binding of patient’s
hyperimmune sera to NeuGcGM3 ganglioside, after the complete
abrogation of the reactivity against racotumomab mAb by adsorb-
ing the patient sera with this Ab2 (Hernández et al., 2008). Also,
antibodies able to react with lung carcinoma tissue sections were
detected in the sera of immunized lung cancer patients (Alfonso
et al., 2007; Neninger et al., 2007).
The ﬁnding that in most of the patients treated with racot-
umomab-Alum vaccine we detected a relatively high titer of
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anti-NeuGcGM3 antibodies of both IgM and IgG isotypes is a
relevant result taking into account that it is difﬁcult to obtain an
IgG antibody response against these antigens (Livingston, 1995).
Even the use of anti-idiotype antibodies as protein mimicries of
gangliosides does not guarantee the induction of this kind of
response. Previously, it was reported that most of the melanoma
patients immunizedwith 1A7mAb able tomimicGD2 ganglioside
developed speciﬁc IgG antibodies against this ganglioside (Foon
et al., 2000). In contrast, when melanoma and SCLC patients
were treated with the anti-idiotype Bec-2 mAb, the percentage
of patients that developed anti-GD3-speciﬁc antibody response
was low, mainly of IgM isotype. The presence of these antibod-
ies was detected by ELISA, but could not be conﬁrmed by TLC
immunostaining or ﬂow cytometry (Ritter et al., 1991; McCaf-
fery et al., 1996; Grant et al., 1999). The differential induction
of antibody responses against gangliosides could be dependent
on their different expression in normal tissues. In fact, stud-
ies previously reported showed the relation between the level of
ganglioside expression in human and murine normal tissues and
their immunogenicity (Chen et al., 2000; Lunn et al., 2000; Bowes
et al., 2002). The strong antibody response against NeuGcGM3
induced in patients by the racotumomab-Alum vaccine can be
explained because NeuGc-containing gangliosides are not self-
antigens in humans (Chou et al., 1998; Irie and Suzuki, 1998;
Olson and Varki, 2003).
Although these studies were not designed to evaluate the ther-
apeutic efﬁcacy of the vaccine, a prolonged survival was observed
in several patients. In particular, the clinical study performed in
NSCLC patients stage IIIb/IV showed encouraging clinical bene-
ﬁt. This clinical trial study included 34 stage IIIb and 37 stage IV
NSCLCpatients. These patientswere treatedwith the anti-idiotype
vaccine, after received standard chemotherapy and radiotherapy,
in a compassionate-use basis study. Patients received ﬁve bi-weekly
injections of 1 mg of racotumomab-Alum, other 10 doses at
28-day intervals and later the patients who maintained a good
performance status continued to be immunized at this same time
interval. No evidence of unexpected or serious adverse effects
was reported, although the patients were repeatedly injected with
racotumomab-Alum and even when some of them received more
than 15 doses of this vaccine. The overall survival of the patients
who entered the study was superior to the one reported (González
et al., 2007) for a group of more than one hundred advanced
NSCLC patients receiving standard oncospeciﬁc treatment in our
country (9.93 vs. 4.53 months). In this study, the survival of the
patients who started racotumomab-Alum with at least disease sta-
bilization after the end of standard therapy and with a PS1, was
signiﬁcant greater (11.50 months) compared with those patients
with progressive disease and/or a PS2 (6.50 months). To assess
whether this advantage in survival could be due to the vaccina-
tion with racotumomab, a comparison was performed with the
median survival time calculated for a subgroup of the control
patients with a PS1 who achieved partial response or stable disease
after the oncospeciﬁc therapy, and there was a statistical signiﬁ-
cant difference between the two groups (11.50 vs. 5.70 months).
Thus, the treatment with the racotumomab-Alum vaccine seems
to prolong survival of this group of patients.
Immunological studies performed in 20 of these patients sug-
gested an association between the induction of antibodies against
NeuGcGM3 and longer survival times (Hernández et al., 2008).
Then, one question we wanted to address was if the generation
of NeuGcGM3 speciﬁc antibodies in patients could have some
biological effect in tumor cells expressing this ganglioside.
Our results from ﬂow cytometry studies, where the sera of
patients were incubated with a cell line expressing NeuGcGM3
and the effect on their viability was studied using the propidium-
iodine exclusion assay, showed that sera of most of the patients
not only recognize the cells, but also directly killed the cells,
by a mechanism independent of complement activation. When
the cells were examined by scanning electron microscopy it was
shown that the cytotoxic hyperimmune patient’s sera produce
large lesions on cell’s membranes (Hernández et al., 2011). These
results contributed to reinforce the therapeutic potential of anti-
idiotype vaccines and the importance of NeuGcGM3 as tumor
target.
Then, a Phase II/III randomized, multicentric, double blind,
clinical study was performed in advanced NSCLC patients look-
ing to the proof of concept with signiﬁcant clinical beneﬁt in the
patients who were treated with the anti-idiotype vaccine in com-
parisonwith the placebo group (manuscript in preparation). Now,
a Phase III multinational clinical trial is ongoing to conﬁrm our
clinical results in advanced NSCLC patients.
CONCLUDING REMARKS
Racotumomab-Alum vaccination has proved to be safe and highly
immunogenic in patients with advanced melanoma, breast and
lung cancer. Racotumomab-Alum vaccination seems to be effec-
tive to prolong overall survival in patients with NSCLC and
preliminary data suggested a correlation between the induction
of antibodies against NeuGcGM3 and increased survival times
of vaccinated patients. The current ongoing Phase III clinical
trial will give a deﬁnitive answer to the potential clinical bene-
ﬁts offered by this vaccine. Furthermore, studies will be required
to determine the more efﬁcient combination with chemotherapy
or other immune interventions to prevail over the tumor-induced
immunosuppression.
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